文献检索文档翻译深度研究

邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

不再提醒

插件&应用

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

高级版

套餐订阅购买积分包

AI 工具

文献检索文档翻译深度研究

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2025

Long-term Protection Associated With COVID-19 Vaccination and Prior Infection.

作者信息

Tenforde Mark W, Link-Gelles Ruth, Patel Manish M

机构信息

CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

出版信息

JAMA. 2022 Oct 11;328(14):1402-1404. doi: 10.1001/jama.2022.14660.

DOI:10.1001/jama.2022.14660

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11331586/

Abstract

摘要

相似文献

[1]

Long-term Protection Associated With COVID-19 Vaccination and Prior Infection.

JAMA. 2022-10-11

[2]

Hybrid Immunity More Protective Than Prior SARS-CoV-2 Infection Alone.

JAMA. 2023-2-21

[3]

Effects of Vaccination and Previous Infection on Omicron Infections in Children.

N Engl J Med. 2022-9-22

[4]

Response to Mishra . re "Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2".

Viral Immunol. 2021-11

[5]

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.

Nat Rev Immunol. 2021-6

[6]

Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.

J Virol. 2024-12-17

[7]

Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance.

PLoS One. 2024-12-31

[8]

Lessons Relearned? H1N1, COVID-19, and Vaccination Planning.

J Public Health Manag Pract. 2021

[9]

Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.

Front Public Health. 2024

[10]

SARS-CoV-2 reinfection and implications for vaccine development.

Hum Vaccin Immunother. 2020-12-1

引用本文的文献

[1]

Evaluating COVID-19 vaccination policy in Québec (Canada) using a data-driven dynamic transmission model.

PLoS Comput Biol. 2025-8-25

[2]

Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection.

Nat Commun. 2024-11-20

[3]

Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated Adults.

Vaccines (Basel). 2024-9-27

[4]

Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023.

PLoS One. 2024

[5]

Vaccination status and disease severity of COVID-19 in different phases of the pandemic.

Hum Vaccin Immunother. 2024-12-31

[6]

Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection.

Vaccines (Basel). 2024-4-26

[7]

A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety.

Infect Med (Beijing). 2023-9-12

[8]

Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine.

JCI Insight. 2023-11-22

[9]

Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.

CPT Pharmacometrics Syst Pharmacol. 2023-10

[10]

Community focus groups about a COVID-19 individual risk assessment tool: access, understanding and usefulness.

BMC Public Health. 2023-9-11

本文引用的文献

[1]

Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.

JAMA. 2022-10-11

[2]

Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers.

JAMA. 2022-8-16

[3]

Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.

JAMA Netw Open. 2022-7-1

[4]

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.

N Engl J Med. 2022-7-7

[5]

Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021.

JAMA. 2022-7-19

[6]

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022.

MMWR Morb Mortal Wkly Rep. 2022-4-29

[7]

Use of At-Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022.

MMWR Morb Mortal Wkly Rep. 2022-4-1

[8]

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.

N Engl J Med. 2022-3-31

[9]

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.

JAMA. 2022-2-15

[10]

Plasma Neutralization of the SARS-CoV-2 Omicron Variant.

N Engl J Med. 2022-2-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

推荐工具

医学文档翻译智能文献检索